TY - JOUR
T1 - Interoperability of Time Series Cytometric Data: A Cross Platform Approach for Modeling Tumor Heterogeneity
AU - Khan, Imtiaz A.
AU - Lupi, Monica
AU - Campbell, Lee
AU - chappell, sally
AU - Brown, Martyn
AU - Wiltshire, Marie
AU - Smith, Paul
AU - Ubezio, Paolo
AU - Errington, Rachel
PY - 2011/2/18
Y1 - 2011/2/18
N2 - The cell cycle, with its highly conserved features, is a fundamental driver for the temporal control of cell proliferation—while abnormal control and modulation of the cell cycle are characteristic of tumor cells. The principle aim in cancer biology is to seek anunderstanding of the origin and nature of innate and acquired heterogeneity at the cellular level, driven principally by temporal and functional asynchrony. A major bottleneck when mathematically modeling these biological systems is the lack of interlinked structured experimental data. This often results in the in silico models failing to translate the specific hypothesis into parameterized terms that enable robust validation and hence would produce suitable prediction tools rather than just simulation tools. The focus has been on linking data originating from different cytometric platforms and cell-based event analysis to inform and constrain the input parameters of a compartmental cell cycle model, hence partly measuring and deconvolving cell cycle heterogeneity within a tumor population. Our work has addressed the concept that the interoperability of cytometric data, derived from different cytometry platforms, can complement as well as enhance cellular parameters space, thus providing a more broader and in-depth view of the cellular systems. The initial aim was to enable the cell cycle model to deliver an improved integrated simulation of the well-defined and constrained biological system. From a modeling perspective, such a cross platform approach has provided a paradigm shift from conventional cross-validation approaches, and from a bioinformatics perspective, novel computational methodology has been introduced for integrating and mapping continuous data with cross-sectional data. This establishes the foundation for developing predictive models and in silico tracking and prediction of tumor progression.
AB - The cell cycle, with its highly conserved features, is a fundamental driver for the temporal control of cell proliferation—while abnormal control and modulation of the cell cycle are characteristic of tumor cells. The principle aim in cancer biology is to seek anunderstanding of the origin and nature of innate and acquired heterogeneity at the cellular level, driven principally by temporal and functional asynchrony. A major bottleneck when mathematically modeling these biological systems is the lack of interlinked structured experimental data. This often results in the in silico models failing to translate the specific hypothesis into parameterized terms that enable robust validation and hence would produce suitable prediction tools rather than just simulation tools. The focus has been on linking data originating from different cytometric platforms and cell-based event analysis to inform and constrain the input parameters of a compartmental cell cycle model, hence partly measuring and deconvolving cell cycle heterogeneity within a tumor population. Our work has addressed the concept that the interoperability of cytometric data, derived from different cytometry platforms, can complement as well as enhance cellular parameters space, thus providing a more broader and in-depth view of the cellular systems. The initial aim was to enable the cell cycle model to deliver an improved integrated simulation of the well-defined and constrained biological system. From a modeling perspective, such a cross platform approach has provided a paradigm shift from conventional cross-validation approaches, and from a bioinformatics perspective, novel computational methodology has been introduced for integrating and mapping continuous data with cross-sectional data. This establishes the foundation for developing predictive models and in silico tracking and prediction of tumor progression.
U2 - 10.1002/cyto.a.21023
DO - 10.1002/cyto.a.21023
M3 - Article
SN - 1552-4930
VL - 79A
SP - 214
JO - Cytometry Part A
JF - Cytometry Part A
IS - 3
ER -